Focus: Actinium Pharmaceuticals specializes in targeted radiotherapy for hematologic malignancies, with a pipeline focused on alpha- and beta-emitting radiopharmaceuticals conjugated to monoclonal antibodies. The company is a clinical-stage biotech with deep expertise in radioisotope-based oncology.
Profile data last refreshed 16m ago · AI intelligence enriched 3w ago
Best suited for scientists or clinicians seeking early-stage, deep technical work in radiotherapy; unsuitable for those seeking rapid career progression or corporate stability.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Actinium Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Actinium Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
+1 more
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles